Xbrane Biopharma AB (XBRANE) - Total Assets
Based on the latest financial reports, Xbrane Biopharma AB (XBRANE) holds total assets worth Skr670.76 Million SEK (≈ $72.18 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Xbrane Biopharma AB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Xbrane Biopharma AB - Total Assets Trend (2012–2025)
This chart illustrates how Xbrane Biopharma AB's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of Xbrane Biopharma AB to evaluate the quality of earnings relative to operating cash generation.
Xbrane Biopharma AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Xbrane Biopharma AB's total assets of Skr670.76 Million consist of 55.9% current assets and 44.2% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 12.9% |
| Accounts Receivable | Skr12.30 Million | 1.8% |
| Inventory | Skr194.27 Million | 28.9% |
| Property, Plant & Equipment | Skr36.00K | 0.0% |
| Intangible Assets | Skr296.46 Million | 44.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Xbrane Biopharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Xbrane Biopharma AB.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xbrane Biopharma AB's current assets represent 55.9% of total assets in 2025, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 12.9% of total assets in 2025, down from 55.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 44.1% of total assets.
Xbrane Biopharma AB Competitors by Total Assets
Key competitors of Xbrane Biopharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Xbrane Biopharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.03 | 1.22 | 1.61 |
| Quick Ratio | 1.38 | 0.71 | 1.78 |
| Cash Ratio | 0.00 | 0.06 | 0.68 |
| Working Capital | Skr245.07 Million | Skr90.20 Million | Skr117.08 Million |
Xbrane Biopharma AB - Advanced Valuation Insights
This section examines the relationship between Xbrane Biopharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.39 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -20.3% |
| Total Assets | Skr671.62 Million |
| Market Capitalization | $22.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xbrane Biopharma AB's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Xbrane Biopharma AB's assets decreased by 20.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Xbrane Biopharma AB (2012–2025)
The table below shows the annual total assets of Xbrane Biopharma AB from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr671.62 Million ≈ $72.28 Million |
-20.28% |
| 2024-12-31 | Skr842.43 Million ≈ $90.66 Million |
+28.91% |
| 2023-12-31 | Skr653.51 Million ≈ $70.33 Million |
-5.36% |
| 2022-12-31 | Skr690.51 Million ≈ $74.31 Million |
+0.30% |
| 2021-12-31 | Skr688.43 Million ≈ $74.09 Million |
+48.44% |
| 2020-12-31 | Skr463.76 Million ≈ $49.91 Million |
+36.83% |
| 2019-12-31 | Skr338.94 Million ≈ $36.48 Million |
+34.03% |
| 2018-12-31 | Skr252.88 Million ≈ $27.21 Million |
+127.91% |
| 2017-12-31 | Skr110.96 Million ≈ $11.94 Million |
-6.05% |
| 2016-12-31 | Skr118.11 Million ≈ $12.71 Million |
+56.79% |
| 2015-12-31 | Skr75.33 Million ≈ $8.11 Million |
+1026.25% |
| 2014-12-31 | Skr6.69 Million ≈ $719.80K |
-27.26% |
| 2013-12-31 | Skr9.20 Million ≈ $989.56K |
+1299.58% |
| 2012-12-31 | Skr657.01K ≈ $70.70K |
-- |
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adu… Read more